3-氯-4-硝基苯胺 | 825-41-2

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类硝化物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯-4-硝基苯胺
• 中文别名: 3-甲氧基氯苄
• 英文名称: 3-chloro-4-nitroaniline
• 英文别名: 1-amino-3-chloro-4-nitrobenzene
• CAS: 825-41-2
• 化学式: C₆H₅ClN₂O₂
• mdl: MFCD00085922
• 分子量: 172.571
• InChiKey: LDSIOPGMLLPSSR-UHFFFAOYSA-N

物化性质

• 熔点：
  158°C
• 沸点：
  366.8±22.0 °C(Predicted)
• 密度：
  1.494
• 最大波长(λmax)：
  350nm(Dioxane)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 海关编码：
  2921420090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P273,P260,P262,P280,P391,P301+P310+P330,P302+P352+P310,P304+P340+P310,P403+P233
• 危险品运输编号：
  2811
• 危险性描述：
  H300+H310+H330,H315,H319,H373,H411
• 储存条件：
  2-8°C

SDS

Name:	3-Chloro-4-nitroaniline 97% Material Safety Data Sheet
Synonym:
CAS:	825-41-2

Section 1 - Chemical Product MSDS Name:3-Chloro-4-nitroaniline 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
825-41-2	3-Chloro-4-nitroaniline	97%	unlisted

Hazard Symbols: T+ N
Risk Phrases: 26/27/28 33 51/53

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Very toxic by inhalation, in contact with skin and if swallowed.
Danger of cumulative effects. Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment.
Potential Health Effects
Eye:
Causes mild eye irritation.
Skin:
May be fatal if absorbed through the skin. Absorption into the body may cause cyanosis (bluish discoloration of skin due to deficient oxygenation of the blood).
Ingestion:
May be fatal if swallowed. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May be fatal if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid immediately. Wash mouth out with water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Dusts at sufficient concentrations can form explosive mixtures with air.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 825-41-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula:
Molecular Weight: 172.57

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, strong bases.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 825-41-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Chloro-4-nitroaniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CHLORONITROANILINES
Hazard Class: 6.1
UN Number: 2237
Packing Group: III
IMO
Shipping Name: CHLORONITROANILINES
Hazard Class: 6.1
UN Number: 2237
Packing Group: III
RID/ADR
Shipping Name: CHLORONITROANILINES
Hazard Class: 6.1
UN Number: 2237
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: T+ N
Risk Phrases:
R 26/27/28 Very toxic by inhalation, in contact with
skin and if swallowed.
R 33 Danger of cumulative effects.
R 51/53 Toxic to aquatic organisms, may cause
long-term adverse effects in the aquatic environment.
Safety Phrases:
S 28 After contact with skin, wash immediately
with...
S 36/37 Wear suitable protective clothing and
gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
S 61 Avoid release to the environment. Refer to
special instructions/safety data sheets.
WGK (Water Danger/Protection)
CAS# 825-41-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 825-41-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 825-41-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯-4-硝基苯胺 在 vasicine 作用下， 以 水 为溶剂， 反应 24.0h， 以85%的产率得到2-氯-4-氨基苯胺
  参考文献：
  名称：

  Vasicine在水中的硝基芳烃的无金属转移加氢：丰富生物碱的有机催化方面的启示

  摘要：

  Vasicine是一种来自Adhatoda vasica叶片的丰富的喹唑啉生物碱，已成功地用于将金属上的硝基芳烃无金属和无碱还原为相应的苯胺。该方法具有化学选择性，可耐受各种可还原的官能团，例如酮，腈，酯，卤素和杂环。在本反应条件下，二硝基芳烃选择性地还原成相应的硝基苯胺。

  DOI：

  10.1021/jo5019415
• 作为产物：
  描述：

  硝基氯苯 在 potassium tert-butylate 、 ammonium pyrrolidinedithiocarbamate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 以72%的产率得到3-氯-4-硝基苯胺
  参考文献：
  名称：

  Nitroarylamines via the Vicarious Nucleophilic Substitution of Hydrogen:  Amination, Alkylamination, and Arylamination of Nitroarenes with Sulfenamides

  摘要：

  A new reaction of sulfenamides with electrophilic arenes under basic conditions is described. The sigma adducts formed from nitroarenes and the anions of sulfenamides undergo elimination of thiol to produce the corresponding o- and/or p-nitroanilines. This reaction is analogous to the known alkylation and hydroxylation of nitroarenes via the vicarious nucleophilic substitution of hydrogen (VNS). The reaction gives access to a wide range of substituted nitroanilines, nitronaphthylamines, and aminoheterocycles. By means of the reaction with N-alkryl- and N-arylsulfenamides, it is possible to obtain N-alkylnitroanilines and nitrodiarylamines. By varying the structure of sulfenamide and the reaction conditions, particularly the nature and concentration of the base, it is possible to control the orientation of amination.

  DOI：

  10.1021/jo970582b
• 作为试剂：
  描述：

  盐酸 、 3-chloro-4-nitroacetanilide 在 氮 、 乙酸乙酯 、 Sodium sulfate-III 、 3-氯-4-硝基苯胺 作用下， 以 水 为溶剂， 反应 3.0h， 以to afford 2.1 g (87%) of the title compound, 3-chloro-4-nitroaniline的产率得到3-氯-4-硝基苯胺
  参考文献：
  名称：

  Anthelmintically active benzenepropanamide derivatives

  摘要：

  本发明涉及一种治疗动物蛔虫病的方法，该方法包括向需要治疗的动物施用化合物公式（I）的驱虫有效量：##STR1## 其中Z是氧或硫；R1是氢或较低烷基；R2、R3、R4和R5独立地是氢、卤素、较低卤代烷基、较低烷氧基、较低卤代烷氧基、硝基、氰基、卤代苯氧基、卤代烷基苯氧基、硫氰酸基或异硫氰酸基，其中R2和R3不能同时为氢，R4和R5也不能同时为氢；或其药学上可接受的盐，并制备有药物组成。本发明还涉及公式（I）中Z为氧的新型驱虫活性苯丙酰胺。

  公开号：

  US05034410A1

文献信息

• PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
  申请人：Arora Nidhi

  公开号：US20120015962A1

  公开（公告）日：2012-01-19

  Compounds of the formula I or II: wherein X, m, Ar, R 1 and R 2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

  式I或II的化合物： 其中X，m，Ar，R1和R2如本文所定义。所述化合物对于治疗IRAK介导的疾病是有用的。
• [EN] ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF<br/>[FR] AGENTS ANTI-INFECTIEUX ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009039134A1

  公开（公告）日：2009-03-26

  This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

  这项发明涉及：(a) 抑制HCV等化合物及其盐；(b) 用于制备这种化合物和盐的中间体；(c) 包括这种化合物和盐的组合物；(d) 制备这种中间体、化合物、盐和组合物的方法；(e) 使用这种化合物、盐和组合物的方法；以及(f) 包括这种化合物、盐和组合物的试剂盒。
• Fabrication of magnetically separable ruthenium nanoparticles decorated on channelled silica microspheres: Efficient catalysts for chemoselective hydrogenation of nitroarenes
  作者：Gauravjyoti D. Kalita、Manash R. Das、Pankaj Das

  DOI：10.1039/d1dt01665b

  日期：——

  were employed as sorbents for the incorporation of ultrasmall Ru nanoparticles (2–5 nm) followed by thermal aggregation of the microspheres for achieving better heterogeneity and low leaching. The Ru decorated Fe3O4–SiO2 microspheres (Ru@Fe3O4–CSM) were applied as chemoselective catalysts to convert more than 20 substituted nitroarenes to corresponding amines with good-to-excellent conversion (77–99%)

  Fe 3 O 4 -SiO 2微球是通过三步合成程序合成的，包括二氧化硅涂层、表面封端和表面改性。这些磁性介孔微球被用作吸附剂，用于掺入超小 Ru 纳米粒子（2-5 nm），然后微球的热聚集以实现更好的异质性和低浸出。Ru修饰的Fe 3 O 4 –SiO 2微球（Ru@Fe 3 O 4-CSM) 用作化学选择性催化剂，在温和条件下将 20 多种取代硝基芳烃转化为相应的胺，转化率 (77-99%) 和选择性 (70-100%) 良好；该催化剂可以在 90 秒（恢复延时）的框架内磁性回收，最多可重复使用 5 次，而不会显着降低活性或选择性。进行磁滞研究以阐明钌装饰材料的磁性行为。
• [EN] URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C<br/>[FR] DÉRIVÉ D'URACILE OU DE THYMINE POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：ABBOTT LAB

  公开号：WO2009039127A1

  公开（公告）日：2009-03-26

  Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.

  本申请涉及一种用于治疗丙型肝炎（HCV）感染的化合物，其化学式为I。所述化合物的结构中，尿嘧啶或胸腺嘧啶衍生物通过苯基与融合的2环环系统（R6）或者通过额外的两原子连接物（L）与5-6环单环（R6）相连。该申请还揭示了两种特定化合物的多晶形和伪多晶形：N-(6(3-叔丁基-5-(2>4-二氧化-3,4-二氢嘧啶-1(2H)-基)2-甲氧基苯基)萘-2-基)甲磺酰胺和(E)-N-(4(3-叔丁基-5-(2,4-二氧化-3,4-二氢嘧啶-1(2H)-基)2-甲氧基-苯乙烯基苯基)甲磺酰胺。
• [EN] BENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE
  申请人：PFIZER

  公开号：WO2021124155A1

  公开（公告）日：2021-06-24

  The invention relates to benzimidazoles of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.

  该发明涉及式（I）的苯并咪唑及其药用盐，其中R1至R6如描述中所定义；它们在医学上的应用；含有它们的组合物；它们的制备方法；以及在这些方法中使用的中间体。式（I）的苯并咪唑是ITK抑制剂，因此在治疗包括特应性皮炎在内的广泛疾病中有潜在用途。